Actualités et vidéos - MOBERG DERMA AB ORD

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication PR Newswire STOCKHOLM, Feb. 7, 2024 STOCKHOLM , Feb. 7, 2024 /PRNewswire/ -- Moberg Pharma ABs (OMX: MOB) marker partner in Sweden - Allderma AB, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals - has now launched sales of MOB-015 under the Terclara ® brand. The interest among pharmacies has been significant for Moberg Pharma's medication against...

MOB-015 is recommended for approval in EU: Moberg Pharma PR Newswire STOCKHOLM, June 28, 2023 STOCKHOLM , June 28, 2023 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) hereby announces that the Decentralized Procedure has ended with a positive outcome and that MOB-015 is recommended for national approval in 13 European countries for the treatment of mild to moderate fungal infections of the nails in adults. The approval in the European Union represents the first marketing authorizations for Moberg...

European marketing authorization application for MOB-015 submitted PR Newswire STOCKHOLM, March 28, 2022 STOCKHOLM , March 28, 2022 /PRNewswire/ -- Moberg Pharma AB (publ) have submitted its marketing authorization application for MOB-015 (nail fungus treatment). The company has submitted the application in Europe through the decentralized procedure, and market approval is expected in 2023. Moberg Pharma have submitted a full application, which offers the possibility of data exclusivity in...

The Medical Products Agency in Sweden will be reference member state for Moberg Pharma's European registration application PR Newswire STOCKHOLM, Dec. 23, 2021 STOCKHOLM , Dec. 23, 2021 /PRNewswire/ -- The Medical Products Agency in Sweden has agreed to be reference member state for Moberg Pharma AB's registration application for MOB-015 (nail fungus treatment). The company will submit the registration application in Europe through the decentralized process, and market approval is expected in...

Moberg Pharma receives approval from the EMA's Paediatric Committee PR Newswire STOCKHOLM, Sept. 22, 2021 STOCKHOLM , Sept. 22, 2021 /PRNewswire/ -- Moberg Pharma AB ( OMX: MOB ) today announces that it has received approval of the pediatric plan for MOB-015 from EMA's paediatric committee (PDCO). This approval enables the company to pursue a full marketing authorization application providing up to ten years of exclusivity in Europe following approval. The company's timeline remains, with...

Moberg Pharmas Year-end report 2020 PR Newswire STOCKHOLM, Feb. 9, 2021 STOCKHOLM , Feb. 9, 2021 /PRNewswire/ -- Financing for both MOB-015 and BUPI PERIOD (JUL 2019- DEC 2020 ) Net revenue SEK 50.5 million (15.6) * EBITDA SEK 19.8 million (-1.7) * Operating profit (EBIT) SEK 16.0 million (-3.0) * Profit after tax SEK 10.2 million (-3.8) * Total profit SEK 8.6 million (499.4) Diluted earnings per share SEK 0.54 (-0.21) * Cash and cash equivalents amounted to SEK 29.3 million (919.1) Comparative...

Moberg Pharma: Announcement of terms for the fully guaranteed rights issue in OncoZenge, timetable for the listing and record date for Lex Asea PR Newswire STOCKHOLM, Jan. 29, 2021 STOCKHOLM , Jan. 29, 2021 /PRNewswire/ -- On November 16, 2020 , OncoZenge AB (publ), Moberg Pharma's subsidiary, announced that the company had secured financing of a total of approximately SEK 70 million ahead of the spin-off and separate listing on Nasdaq First North Growth Market. Today, the Board of Moberg Pharma...

New number of shares and votes in Moberg Pharma AB (publ) PR Newswire STOCKHOLM, Jan. 29, 2021 STOCKHOLM , Jan. 29, 2021 /PRNewswire/ -- During January 2021 , the registered number of shares and votes in Moberg Pharma AB (OMX: MOB) ("Moberg Pharma" or the "Company") has increased due to the completion of the previously announced rights issue, and the final conversion of convertible notes issued pursuant to the financing agreement entered into between the Company and Nice & Green S.A. on March...

OncoZenge announces issue of European Patent related to BupiZenge® PR Newswire STOCKHOLM, Jan. 7, 2021 STOCKHOLM , Jan. 7, 2021 /PRNewswire/ -- OncoZenge AB (publ), Moberg Pharma's subsidiary, today announced that the European Patent Office (EPO) has granted patent 3 284 459 which protects BupiZenge ® , currently in development for treatment of pain due to oral mucositis. The patent is expected to be in effect until 2032. The new patent protects sustained-release lozenge containing...

OncoZenge raises MSEK 10 ahead of spin-off and separate listing PR Newswire STOCKHOLM, Dec. 11, 2020 STOCKHOLM , Dec. 11, 2020 /PRNewswire/ -- OncoZenge AB (publ) ("OncoZenge"), Moberg Pharma AB (publ)'s subsidiary, has today resolved on a directed share issue in accordance with the press release from November 16 th , 2020 (the "Directed Issue"). The Directed Issue of MSEK 10 is the first step of the secured financing in OncoZenge of MSEK 70 in total. The share issue is carried out to secure...

Moberg Pharma obtains positive decision from the Swedish Tax Agency regarding the Lex Asea distribution of the shares in OncoZenge PR Newswire STOCKHOLM, Nov. 30, 2020 STOCKHOLM , Nov. 30, 2020 /PRNewswire/ -- Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") has obtained a positive decision confirming that the Swedish Tax Agency shares the Company's assessment that the Company's proposed distribution of the shares in OncoZenge qualifies as a Lex Asea distribution in accordance with...

Invitation to market update in Moberg Pharma on November 25th PR Newswire STOCKHOLM, Nov. 23, 2020 STOCKHOLM , Nov. 23, 2020 /PRNewswire/ -- On November 25 th , 2020, at 02:00 am (CET) , investors, analysts and journalists are invited to participate in a digital company presentation. Moberg pharma recently announced its intention to distribute its subsidiary OncoZenge through a Lex ASEA distribution before listing the company on Nasdaq First North Growth Market, as well as securing financing...

OncoZenge secures approximately SEK 70 million in financing ahead of spin-off and separate listing PR Newswire STOCKHOLM, Nov. 16, 2020 STOCKHOLM , Nov. 16, 2020 /PRNewswire/ -- Moberg Pharma's subsidiary OncoZenge has received binding undertakings regarding a directed issue of shares of SEK 10 million and a fully secured rights issue of shares of approximately SEK 60 million . The investors, which include John Fällström, Linc AB and Moberg Pharma's largest shareholder, Östersjöstiftelsen,...

Extended fiscal year July 2019 - December 2020 Interim report July - September 2020 PR Newswire STOCKHOLM, Nov. 10, 2020 STOCKHOLM , Nov. 10, 2020 /PRNewswire/ -- Registration preparations in Europe , Financing for MOB-015 secured and spin-off of BUPI PERIOD (JUL 2019-SEP 2020) Net revenue SEK 50.5 million (15.6) * EBITDA SEK 24.4 million (-3.0) * Operating profit (EBIT) SEK 21.2 million (-4.2) * Profit after tax SEK 15.4 million (-4.7) * Total comprehensive income SEK 15.4 million (499.4)...

Moberg Pharma decides on fully guaranteed rights issue of approximately SEK 150 million PR Newswire STOCKHOLM, Nov. 6, 2020 STOCKHOLM , Nov. 6, 2020 /PRNewswire/ -- The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) ("Moberg Pharma" or "the Company") has today resolved to carry out a fully guaranteed issue of new ordinary shares and warrants ("Units") with preferential rights for existing shareholders (the "Rights Issue") of approximately SEK 150 million before transaction costs. The...

Moberg Pharma intends to distribute and separately list BupiZenge® (BUPI) PR Newswire STOCKHOLM, Nov. 6, 2020 STOCKHOLM , Nov. 6, 2020 /PRNewswire/ -- The Board of Directors of Moberg Pharma AB (OMX: MOB) today announces its intention to distribute the operations of BupiZenge ® (BUPI) to the shareholders of Moberg Pharma by distributing 90 percent of the shares in a subsidiary (name to be changed to OncoZenge AB) through a so-called Lex ASEA distribution, and convenes an extraordinary general...

Moberg Pharma intends to submit a registration application in Europe in 2021 PR Newswire STOCKHOLM, Oct. 14, 2020 STOCKHOLM , Oct. 14, 2020 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announced today its decision to request pre-submission meetings with regulatory agencies, with the goal of submitting a registration application in the second half of 2021 in Europe . In June, Moberg Pharma presented topline results from the second of two clinical Phase 3 studies for MOB-015. In the European study...

Moberg Pharma: Interim report April - June 2020 PR Newswire STOCKHOLM, Aug. 11, 2020 STOCKHOLM , Aug. 11, 2020 /PRNewswire/ -- The Primary endpoint was met in the Phase 3 study TWELVE MONTH PERIOD (JUL 2019- JUN 2020 ) Net revenue SEK 50.5 million (15.6) * EBITDA SEK 29.0 million (-3.0) * Operating profit (EBIT) SEK 26.4 million (-4.2) * Profit after tax SEK 20.0 million (-4.7) * Total comprehensive income SEK 20.0 million (499.4) Diluted earnings per share SEK 1.06 (-0.27) * Cash and cash...

Appointment of Chief Medical Officer at Moberg Pharma PR Newswire STOCKHOLM, July 30, 2020 STOCKHOLM , July 30, 2020 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces the appointment of Dr Cindy Wong as Chief Medical Officer of Moberg Pharma. Dr Wong will during the fall be joining the management team at Moberg Pharma coming from a previous position as Vice President and Head of Global Clinical Development at Metz Pharmaceuticals GmbH. Moberg Pharma is pleased to announce the appointment of...

New number of Shares and Votes in Moberg Pharma AB (publ) PR Newswire STOCKHOLM, June 30, 2020 STOCKHOLM , June 30, 2020 /PRNewswire/ -- During June 2020 , the registered number of shares and votes in Moberg Pharma AB (OMX: MOB) ("Moberg Pharma" or the "Company") has increased due to conversion of convertible notes issued pursuant to the financing agreement entered into between the Company and Nice & Green S.A. on March 23rd, 2020 . The total number of shares and votes in the Company has...